Suppr超能文献

血液透析患者中心静脉狭窄或闭塞经皮腔内血管成形术“母子”同轴双导管技术的长期疗效。

Long-Term Outcome of a "Mother-Child" Coaxial Dual-Catheter Technique for Percutaneous Transluminal Angioplasty of Central Vein Stenosis or Occlusion in Hemodialysis Patients.

机构信息

Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Department of Medical, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

出版信息

J Endovasc Ther. 2024 Aug;31(4):643-650. doi: 10.1177/15266028221136434. Epub 2022 Nov 16.

Abstract

PURPOSE

This study aims to evaluate the long-term outcome and prognostic factors of a "mother-child" coaxial dual-catheter technique for percutaneous transluminal angioplasty (PTA) in the treatment of central vein stenosis (CVS) or central vein occlusion (CVO).

MATERIALS AND METHODS

During September 2017 to August 2020, totally, 76 hemodialysis patients with symptomatic CVS or CVO were treated with PTA using the mother-child technique. The success rate, complications, and follow-up information were collected. Cox proportional hazard analysis was used to explore the predicting factors of primary patency. Primary patency rates of different subgroups were generated with the Kaplan-Meier analysis and compared using the log-rank (Mantel-Cox) test.

RESULTS

There were 31 CVS patients and 45 CVO patients who presented with 114 PTAs. The initial procedure success rate was 98.25%. By the end of the follow-up, 57 patients (75%) had maintained functioning fistula after initial or repeated PTAs. The primary patency rates were 88.75% at 3 months, 73.36% at 6 months, 55.83% at 12 months, and 50.75% at 18 months. The secondary patency rates were 97.14% at 6 months, 87.66% at 12 months, and 82.18% at 24 months. The predictors for primary patency were history diabetes mellitus (hazard ratio [HR] = 3.1, 95% confidence interval [CI]: 1.31-7.30, = .010), abnormal white blood cell count (HR = 1.44, 95% CI: 1.18-1.75, < .001), lesion at subclavian-innominate vein (HR=2.75, 95% CI: 1.34-5.63, = .006), and occlusion (HR=0.33, 95% CI: 0.14-0.76, = .010). The primary patency was significantly lower in the subclavian-innominate vein subgroup, with a median primary patency of 4.5 (3-12.75) months, than in the nonsubclavian-innominate vein subgroup (8.5 [5-13] months; = .005). The median duration of each PTA was 8 months for the first PTA, 7.5 months for the second PTA, and 5 months for the third PTA. There was no significant difference in the patency duration of repeated PTAs and the primary PTA ( = .389).

CONCLUSIONS

The mother-child coaxial dual-catheter technique has a good success rate and acceptable primary patency in the treatment of hemodialysis patients with CVS or CVO. Repeated PTA is as effective as the primary PTA.

CLINICAL IMPACT

This is the follow up report on the "Mother-Child" coaxial dual-catheter technique for percutaneous transluminal angioplasty of central vein stenosis or occlusion in hemodialysis patients since we first presented it in 2019. In this paper, we can see that the long-term patency rate of this technique for central venous disease is satisfactory, and repeated use of this technique does not affect the patency time. Compared with other literature reports, the surgical success rate of this technique is significantly improved. Therefore, this technique is worth popularizing in the treatment of central venous disease.

摘要

目的

本研究旨在评估“子母”同轴双导管技术在经皮腔内血管成形术(PTA)治疗中心静脉狭窄(CVS)或中心静脉闭塞(CVO)中的长期疗效和预后因素。

材料与方法

2017 年 9 月至 2020 年 8 月,共有 76 例有症状 CVS 或 CVO 的血液透析患者采用子母技术行 PTA 治疗。收集手术成功率、并发症和随访信息。采用 Cox 比例风险分析探讨主要通畅率的预测因素。采用 Kaplan-Meier 分析生成不同亚组的主要通畅率,并使用对数秩(Mantel-Cox)检验比较。

结果

31 例 CVS 患者和 45 例 CVO 患者共行 114 次 PTA。初始手术成功率为 98.25%。在随访结束时,57 例(75%)患者在初次或重复 PTA 后维持功能良好的瘘管。3 个月、6 个月、12 个月和 18 个月的主要通畅率分别为 88.75%、73.36%、55.83%和 50.75%。次要通畅率分别为 97.14%、87.66%和 82.18%。主要通畅率的预测因素为糖尿病病史(风险比[HR] = 3.1,95%置信区间[CI]:1.31-7.30, =.010)、白细胞计数异常(HR = 1.44,95%CI:1.18-1.75, <.001)、锁骨下-无名静脉病变(HR = 2.75,95%CI:1.34-5.63, =.006)和闭塞(HR = 0.33,95%CI:0.14-0.76, =.010)。锁骨下-无名静脉亚组的主要通畅率明显低于非锁骨下-无名静脉亚组(中位数分别为 4.5 [3-12.75]个月和 8.5 [5-13]个月; =.005)。首次 PTA 的中位时间为 8 个月,第二次 PTA 为 7.5 个月,第三次 PTA 为 5 个月。重复 PTA 的通畅时间与初次 PTA 无显著差异( =.389)。

结论

子母同轴双导管技术治疗血液透析患者 CVS 或 CVO 的成功率高,主要通畅率可接受。重复 PTA 与初次 PTA 同样有效。

临床意义

这是我们自 2019 年首次提出“子母”同轴双导管技术治疗中心静脉狭窄或闭塞的经皮腔内血管成形术以来,对该技术治疗血液透析患者中心静脉疾病的长期随访报告。本文可以看出,该技术治疗中心静脉疾病的长期通畅率令人满意,且重复使用该技术并不影响通畅时间。与其他文献报告相比,该技术的手术成功率显著提高。因此,该技术在中心静脉疾病的治疗中值得推广。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验